Advanced Science· 2026Q1
In Situ Genetic Engineering Facilitates MMP‐9‐Responsive TIMP1 Release Through Proteolytic Cleavage to Boost Diabetic Wound Healing
- 0citations
- Q1SCImago
- 2026year
Short summary
A novel MMP-9-responsive protein release system (M9RR) enables targeted release of TIMP1 in diabetic wounds, significantly improving healing in mice by neutralizing excessive MMP-9 activity.
AI-generated from the title and abstract; the full text is not read.
Key points
- Developed an MMP-9-responsive protein release system (M9RR) for targeted TIMP1 delivery.
- M9RR releases TIMP1 via cleavage of a peptide linker by MMP-9, specifically in high-MMP-9 wound environments.
- In vitro, M9RR showed MMP-9 specificity and protected cells from MMP-9 damage.
- In diabetic mice, TIMP1 M9RR significantly improved wound healing metrics (contraction, granulation, epithelialization, collagen remodeling).
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Diabetic Foot Ulcer (DFU), a severe chronic diabetes complication with low healing and high recurrence rates, is a major global health challenge. Overexpression of matrix metalloproteinase‐9 (MMP‐9) and the consequent MMP‐9/TIMP1 (tissue inhibitor of metalloproteinase 1) imbalance delays healing by degrading the extracellular matrix, impairing granulation tissue formation, and exacerbating inflammation. Conventional therapies do not dynamically respond to fluctuating protease levels in chronic wounds. This study introduces an MMP‐9‐responsive protein release system (M9RR), where the therapeutic protein (i.e., TIMP1) is linked to a membrane‐anchoring domain at its C‐terminus via an MMP‐9‐cleavable peptide, thereby exposing the fusion protein to the extracellular side of cell membranes. The system enables targeted release of TIMP1 in high‐MMP‐9 microenvironments, thereby neutralizing excessive MMP‐9 activity. In vitro, M9RR demonstrates MMP‐9 specificity, broad mammalian cell applicability, and protection of HaCaT keratinocytes and BJ fibroblasts from MMP‐9‐induced damage. In db/db diabetic mice, the MMP‐9‐responsive TIMP1 release system (TIMP1 M9RR ) significantly improves wound contraction, granulation tissue formation, epithelial regeneration, and collagen remodeling. Additionally, a cryomicroneedle (CryoMNs)‐based co‐delivery system for basic fibroblast growth factor (bFGF) and TIMP1 M9RR shows effective diabetic wound healing. This modular M9RR system offers a precise, adaptive therapeutic strategy for DFU and holds promise for other MMP‐related diseases.
The authors' abstract, as published at the source. Advanced Science, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Rehabilitation
RehabilitationMedicine